SkinDermic® business strategy is to partner its proprietary drug candidates with pharmaceutical and biotech companies for clinical development, manufacturing and commercialization of its novel drugs.
SkinDermic® owns a pipeline of new drugs for the treatment of dermatological diseases (Acne, Kaposi’s sarcoma).
The Company has 5 first-in-class, internally discovered, molecules candidates for clinical development including:
- SDA-001, SDA-002 and SDA-003, anti-inflammatory molecules developed for topical use for human inflammatory acne
- SDK-001 and SDK-002, pro-apoptotic molecules for human cutaneous Kaposi’s sarcoma lesions that act selectively in HHV8 infected cells.